Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 22578202)

1.

Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma.

Trafalis DT, Alifieris C, Krikelis D, Tzogkas N, Stathopoulos GP, Athanassiou AE, Sitaras NM.

Int J Clin Pharmacol Ther. 2012 Jul;50(7):490-9. doi: 10.5414/CP201688.

PMID:
22578202
2.

Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.

Garcia AA, Roman L, Muderspach L, O'meara A, Facio G, Edwards S, Burnett A.

Cancer Invest. 2005;23(8):665-70.

PMID:
16377584
3.

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.

Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G, Komaki R, McMurtrey MJ, Hong WK.

Cancer. 1995 Dec 1;76(11):2230-6.

PMID:
8635025
4.

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.

Pennucci MC, Ardizzoni A, Pronzato P, Fioretti M, Lanfranco C, Verna A, Giorgi G, Vigani A, Frola C, Rosso R.

Cancer. 1997 May 15;79(10):1897-902.

PMID:
9149015
5.

First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial.

Arrieta Ó, Medina LA, Estrada-Lobato E, Hernández-Pedro N, Villanueva-Rodríguez G, Martínez-Barrera L, Macedo EO, López-Rodríguez V, Motola-Kuba D, Corona-Cruz JF.

Br J Cancer. 2012 Mar 13;106(6):1027-32. doi: 10.1038/bjc.2012.44. Epub 2012 Feb 21.

6.

Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.

Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK; Pemetrexed expanded access program investigators.

J Thorac Oncol. 2006 Jul;1(6):506-12. Erratum in: J Thorac Oncol. 2006 Sep;1(7):621.

PMID:
17409909
7.

Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).

Parra HS, Tixi L, Latteri F, Bretti S, Alloisio M, Gravina A, Lionetto R, Bruzzi P, Dani C, Rosso R, Cosso M, Balzarini L, Santoro A, Ardizzoni A.

Cancer. 2001 Aug 1;92(3):650-6.

PMID:
11505411
8.

Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.

Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G.

In Vivo. 2006 Nov-Dec;20(6A):715-8.

9.

A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.

Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M.

Am J Clin Oncol. 2008 Oct;31(5):476-80. doi: 10.1097/COC.0b013e31816a6221.

PMID:
18838885
10.

Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.

Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J.

J Thorac Oncol. 2008 Jul;3(7):764-71. doi: 10.1097/JTO.0b013e31817c73ec.

PMID:
18594323
11.

The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.

Andreopoulou E, Ross PJ, O'Brien ME, Ford HE, Priest K, Eisen T, Norton A, Ashley S, Smith IE.

Ann Oncol. 2004 Sep;15(9):1406-12.

12.

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M.

Lung Cancer. 2012 Mar;75(3):360-7. doi: 10.1016/j.lungcan.2011.08.011. Epub 2011 Sep 19.

PMID:
21937142
13.

Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.

Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, Fountzilas G, Syrigos KN.

Clin Lung Cancer. 2010 Jan;11(1):30-5. doi: 10.3816/CLC.2010.n.005.

PMID:
20085865
14.

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.

van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G; European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada.

J Clin Oncol. 2005 Oct 1;23(28):6881-9.

15.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.

J Clin Oncol. 2003 Jul 15;21(14):2636-44.

PMID:
12860938
16.
17.

Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.

Bottomley A, Gaafar R, Manegold C, Burgers S, Coens C, Legrand C, Vincent M, Giaccone G, Van Meerbeeck J; EORTC Lung-Cancer Group; National Cancer Institute, Canada.

J Clin Oncol. 2006 Mar 20;24(9):1435-42. Epub 2006 Jan 30. Erratum in: J Clin Oncol. 2006 Jun 1;24(16):2601. Gaafa, Rabab [corrected to Gaafar, Rahab].

18.

A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.

Vergote I, Schilder RJ, Pippitt CH Jr, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix L, Leach JW, Ananda S, Nanayakkara N, Melara R, Bass MB, Litten J, Adewoye H, Wenham RM.

Gynecol Oncol. 2014 Oct;135(1):25-33. doi: 10.1016/j.ygyno.2014.07.003. Epub 2014 Jul 11.

PMID:
25019569
19.

Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.

Mirchandani D, Hochster H, Hamilton A, Liebes L, Yee H, Curtin JP, Lee S, Sorich J, Dellenbaugh C, Muggia FM.

Clin Cancer Res. 2005 Aug 15;11(16):5912-9.

20.

Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.

Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J, Griffin M, Fishwick K, Boddy AV, Verrill M, Calvert H.

J Clin Oncol. 2002 Aug 15;20(16):3533-44.

PMID:
12177114
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk